EP0491443B1 - Progestagen-only contraceptive - Google Patents
Progestagen-only contraceptive Download PDFInfo
- Publication number
- EP0491443B1 EP0491443B1 EP91203328A EP91203328A EP0491443B1 EP 0491443 B1 EP0491443 B1 EP 0491443B1 EP 91203328 A EP91203328 A EP 91203328A EP 91203328 A EP91203328 A EP 91203328A EP 0491443 B1 EP0491443 B1 EP 0491443B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- desogestrel
- ketodesogestrel
- dosage units
- mixtures
- progestogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000583 progesterone congener Substances 0.000 title claims description 36
- 239000003433 contraceptive agent Substances 0.000 title claims description 18
- 230000002254 contraceptive effect Effects 0.000 title claims description 15
- WAHQVRCNDCHDIB-QZYSPNBYSA-N [(3s,8r,9s,10r,13s,14s,17r)-17-acetyl-17-acetyloxy-6,10,13-trimethyl-1,2,3,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-yl] 3-cyclopentylpropanoate Chemical compound O([C@@H]1C=C2C(C)=C[C@H]3[C@@H]4CC[C@]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)(OC(=O)C)C(C)=O)C(=O)CCC1CCCC1 WAHQVRCNDCHDIB-QZYSPNBYSA-N 0.000 title 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 claims abstract description 32
- 239000000203 mixture Substances 0.000 claims abstract description 32
- 229960004976 desogestrel Drugs 0.000 claims abstract description 31
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 8
- 238000012377 drug delivery Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims 3
- 239000004615 ingredient Substances 0.000 claims 2
- 230000000757 progestagenic effect Effects 0.000 claims 1
- 231100000546 inhibition of ovulation Toxicity 0.000 abstract description 5
- 229940127234 oral contraceptive Drugs 0.000 abstract description 4
- 239000003539 oral contraceptive agent Substances 0.000 abstract description 4
- 208000025661 ovarian cyst Diseases 0.000 abstract description 4
- 230000027758 ovulation cycle Effects 0.000 abstract description 4
- 230000002085 persistent effect Effects 0.000 abstract description 4
- 206010027514 Metrorrhagia Diseases 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 230000000717 retained effect Effects 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 22
- 238000000034 method Methods 0.000 description 13
- 239000006187 pill Substances 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 2
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000011247 coating layer Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229940053934 norethindrone Drugs 0.000 description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- ZKFNOUUKULVDOB-UHFFFAOYSA-N 1-amino-1-phenylmethyl phosphonic acid Chemical compound OP(=O)(O)C(N)C1=CC=CC=C1 ZKFNOUUKULVDOB-UHFFFAOYSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 208000009774 Follicular Cyst Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 229920002472 Starch Chemical class 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 229920002678 cellulose Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000037416 cystogenesis Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960002941 etonogestrel Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- 229960003846 melengestrol acetate Drugs 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000000624 ovulatory effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000008107 starch Chemical class 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
Definitions
- the invention relates generally to contraceptive preparations, and more specifically to a contraceptive regimen involving only the administration of desogestrel, 3-ketodesogestrel or mixtures thereof.
- a progestogen is administered from at least the fifth day to the twenty-fifth day of the menstrual cycle, the dosage of the progestogen being greater during the last seven days of administration than it is in the first seven days.
- U.S. Patent No. 4,018,919 to Eli Lilly & Co. describes a sequential oral contraceptive method using two different types of progestational agents. These different types of progestational agents are a Type A progestin (e.g. norethindrone) and Type B progestin (e.g. chlormadione acetate).
- Type A progestin e.g. norethindrone
- Type B progestin e.g. chlormadione acetate
- U.S. Patent 4,171,358 to Eli Lilly & Co. describes another contraceptive method in which a progestin (e.g. chlormadione acetate) is administered on days 6 to 16 of the menstrual cycle, followed by a period in which no hormone is administered.
- a progestin e.g. chlormadione acetate
- DT 1,950,857 to Merck Patent GmbH describes a progestogen-only contraceptive pack containing 28 dosage units, 14 to 18 of which are "blanks", containing no contraceptive steroid.
- Disclosed progestogens include chlormadione acetate, megestrol acetate, melengestrol acetate and medroxyprogesterone acetate.
- a similar regimen is disclosed in DT 1,965,881, also to Merck Patent GmbH.
- U.S. Patent No. 3,822,355 to Biological Concepts Inc. describes a method of controlling the ovulatory cycle in women involving administering placebo tablets daily for 12 to 16 days; followed administering daily tablets containing 2 to 20 mg progestogen (e.g. norethindrone) for four days; finally followed by administering tablets containing 10 to 40 % of the previous progestogen dosage for the remainder of the cycle.
- progestogen e.g. norethindrone
- Progestogen-only pills are a preferred method of contraception for breast-feeding mothers, older women, women for whom estrogen is contraindicated, women who are hypertensive, and women who develop migraine headaches when taking a combined pill (i.e. one containing an estrogen and progestogen component). See, e.g. "Contraception for women over the age of 35", IPPF Medical Bulletin , 22: 3-4 (1988) and Howie, PW "The progestogen-only pill", Brit. J. Obstet. Gynaecol. , 92: 1001-2 (1985).
- the invention thus includes a drug delivery system containing daily oral dosage units, each unit containing from 70 to 80 micrograms of desogestrel, 3-ketodesogestrel, or mixtures thereof.
- the invention also includes a pharmaceutical product (i.e. the dosage units or the package containing the dosage units), a method of using the product, and a process of manufacturing the pharmaceutical product.
- a pharmaceutical product i.e. the dosage units or the package containing the dosage units
- a method of using the product i.e. the dosage units or the package containing the dosage units
- a process of manufacturing the pharmaceutical product i.e. the process of manufacturing the pharmaceutical product.
- the invention also includes a method of providing contraception for a pre-menopausal woman involving orally administering to the woman, on a daily basis, 70 to 80 micrograms of desogestrel, 3-ketodesogestrel, or mixtures thereof.
- Progestogens for use with the invention are 3-ketodesogestrel ("etonogestrel”) and desogestrel.
- Desogestrel has the chemical name 13-ethyl-11-methylene-18,19-dinor-17 ⁇ -pregn-4-en-20-yn-17-ol. Desogestrel is believed to be metabolized in the body into 3-ketodesogestrel. In the dosage units, 75 ⁇ g of desogestrel or 3-ketodesogestrel are preferably used. Both compounds are available from Organon International, bv of Oss, The Netherlands.
- the progestogen (“contraceptive steroid”), is incorporated into dosage units for oral administration.
- dosage unit generally refers to physically discrete units suitable as unitary dosages for humans, each containing a predetermined quantity of active material calculated to produce the desired effect.
- dosage units e.g. tablets
- conventional additives e.g. fillers, colorants, polymeric binders and the like
- any pharmaceutically acceptable additive which does not interfere with the function of the active compounds can be used in the one or more of the compositions.
- Suitable carriers with which the compositions can be administered include lactose, starch, cellulose derivatives and the like used in suitable amounts. Lactose is a preferred carrier. Mixtures of carriers can also be used.
- a process of manufacturing the combination and contraceptive kit of the invention comprises mixing predetermined quantities of desogestrel, 3-ketodesogestrel, or mixtures thereof with predetermined quantities of excipients and converting the mixture into dosage units containing 70 to 80 ⁇ g of desogestrel or 3-ketodesogestrel.
- Converting the mixture into dosage units generally involves molding the mixture into a tablet, filling a capsule with a dried mixture, or filling a capsule with a wet mixture.
- a preferred process of manufacturing the pharmaceutical product according to the invention involves incorporating the desired dosages of contraceptive steroid (i.e. desogestrel, 3-ketodesogestrel, or mixtures thereof) into tablets by techniques such as wet granulation tableting techniques.
- the package containing the dosage units will contain between 7 and 180, preferably 28, dosage units.
- a preferred method of contraception using the invention comprises administering, orally, to a female of child-bearing age, 70 to 80 ⁇ g of desogestrel, 3-ketodesogestrel, or mixtures thereof daily. After the completion of one cycle of the regimen, the regimen may be repeated for as long as contraception is desired.
- Desogestrel and 3-ketodesogestrel are 70 to 80 % bioavailable after oral administration in comparison with non-enteral forms of administration (e.g. via an implant).
- composition per tablet: Compound Amount (mg/tablet) desogestrel 0.075 corn starch 6.500 povidone 1.950 stearic acid 0.650 colloidal silicone dioxide 0.650 dl- ⁇ -tocopherol 0.080 lactose qsad 65.000 Coating layer: (filmcoat-dry) Compound Amount (mg/tablet) hydroxypropylmethylcellulose 0.75 polyethylene glycol 400 0.15 titanium dioxide 0.1125 talc 0.1875
- the tablets were packed in push-through packs.
- the push through packs are placed in folding cartons, which are additionally sealed in aluminum sachets.
- compositions of tablets Compound Amount (mg/tablet) 3-ketodesogestrel 0.075 corn starch 6.500 povidone 1.950 stearic acid 0.650 colloidal silicone dioxide 0.650 dl- ⁇ -tocopherol 0.080 lactose qsad 65.000 Coating layer: Compound Amount (mg/tablet) hydroxypropylmethylcellulose 0.75 polyethylene glycol 400 0.15 titanium dioxide 0.1125 talc 0.1875
- the tablets of EXAMPLE I along with similar tablets containing 0.030 and 0.050 mg of desogestrel were tested in 44 healthy female volunteers in a non-public, double-blind randomized study. Ovulation was completely inhibited with the tablets of EXAMPLE I (i.e. those containing 0.075 mg desogestrel), whereas incomplete inhibition of ovulation occurred at the other lower doses. Furthermore, the use of the tablets of EXAMPLE I also had the lowest percentage of bleeding and spotting days (mean of 22%) in comparison to 0.030 mg desogestrel (mean of 32%) and 0.050 mg (mean of 33%). Amenorrhea occurred only once in the group administered the tablets of EXAMPLE I.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP90203371 | 1990-02-17 | ||
EP90203371 | 1990-12-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0491443A1 EP0491443A1 (en) | 1992-06-24 |
EP0491443B1 true EP0491443B1 (en) | 1996-03-13 |
Family
ID=8205203
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP91203328A Expired - Lifetime EP0491443B1 (en) | 1990-12-17 | 1991-12-12 | Progestagen-only contraceptive |
Country Status (20)
Country | Link |
---|---|
US (1) | US5461041A (xx) |
EP (1) | EP0491443B1 (xx) |
JP (1) | JPH04290829A (xx) |
KR (1) | KR100221008B1 (xx) |
CN (1) | CN1036834C (xx) |
AT (1) | ATE135218T1 (xx) |
AU (1) | AU649082B2 (xx) |
CA (1) | CA2057714C (xx) |
DE (2) | DE69117902T2 (xx) |
DK (1) | DK0491443T3 (xx) |
ES (1) | ES2087237T3 (xx) |
FI (1) | FI98984C (xx) |
GR (1) | GR3020180T3 (xx) |
IE (1) | IE71202B1 (xx) |
LU (1) | LU90341I2 (xx) |
NL (1) | NL990003I2 (xx) |
NO (2) | NO178686C (xx) |
NZ (1) | NZ240969A (xx) |
PT (1) | PT99818B (xx) |
ZA (1) | ZA919732B (xx) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE202010010589U1 (de) | 2010-07-22 | 2010-10-14 | Bayer Schering Pharma Aktiengesellschaft | Estrogenfreie Formulierung zur oralen Kontrazeption, bevorzugt verwendbar für Frauen mit bewusster/unbewusster Laktoseintoleranz oder mit bewusster laktosefreier Kontrazeption |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4133680A1 (de) * | 1991-10-11 | 1993-04-15 | Metallgesellschaft Ag | Stabilisierte staerke, verwendung der stabilisierten staerke und verfahren zu ihrer herstellung |
DE4227989A1 (de) * | 1992-08-21 | 1994-06-09 | Schering Ag | Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel |
US5395627A (en) * | 1992-09-04 | 1995-03-07 | Akzo N.V. | Pharmaceutical granulate |
US6407082B1 (en) * | 1996-09-13 | 2002-06-18 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a vitamin D compound |
ZA949929B (en) * | 1993-12-23 | 1995-08-23 | Akzo Nobel Nv | Sugar-coated pharmaceutical dosage unit. |
DE4405590C1 (de) * | 1994-02-22 | 1995-07-20 | Hesch Rolf Dieter Prof Dr Med | Mittel zur postmenopausalen Hormonbehandlung |
DK0782449T3 (da) * | 1994-09-22 | 2003-08-04 | Akzo Nobel Nv | Fremgangsmåde til fremstilling af doseringsenheder ved vådgranulering |
US6028064A (en) | 1996-09-13 | 2000-02-22 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of progestin products |
US6765002B2 (en) | 2000-03-21 | 2004-07-20 | Gustavo Rodriguez | Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium |
US6034074A (en) | 1996-09-13 | 2000-03-07 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a Vitamin D compound |
US6511970B1 (en) | 1996-09-13 | 2003-01-28 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium |
WO1999051214A2 (en) * | 1998-04-07 | 1999-10-14 | Akzo Nobel N.V. | Progestogen-only contraceptive kit |
AU5619399A (en) * | 1998-08-11 | 2000-03-06 | Akzo Nobel N.V. | Progestogen-only contraceptive kit providing good cycle control |
US20040176336A1 (en) * | 2000-03-21 | 2004-09-09 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
US20050113351A1 (en) * | 2000-03-21 | 2005-05-26 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
US20010044431A1 (en) * | 2000-03-21 | 2001-11-22 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
GB0114746D0 (en) | 2001-06-16 | 2001-08-08 | Boots Co Plc | Medicinal composition |
US6574033B1 (en) | 2002-02-27 | 2003-06-03 | Iridigm Display Corporation | Microelectromechanical systems device and method for fabricating same |
TW200403075A (en) * | 2002-05-29 | 2004-03-01 | Akzo Nobel Nv | Progestagenic dosage units |
BRPI0409860A (pt) * | 2003-04-29 | 2006-05-16 | Akzo Nobel Nv | processo de solidificação anti-solvente |
DE102005053771A1 (de) * | 2005-11-09 | 2007-05-10 | Grünenthal GmbH | Darreichform zur hormonalen Kontrazeption |
EP2730284A1 (en) * | 2012-11-12 | 2014-05-14 | Naari AG | Levonorgestrel-only-composition for optimized oral contraception with defined levonorgestrel content, dosage regimen and pharmaceutical preparation |
WO2017000081A1 (zh) * | 2015-06-30 | 2017-01-05 | 上海交通大学 | Etonogestrel在制备抗前列腺癌产品中的应用 |
US11679114B2 (en) | 2021-07-26 | 2023-06-20 | Navad Life Sciences Pte | Progestogen-only oral contraception |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4066757A (en) * | 1973-03-26 | 1978-01-03 | Ortho Pharmaceutical Corporation | Oral contraceptive regimen |
ATE86484T1 (de) * | 1987-08-08 | 1993-03-15 | Akzo Nv | Kontrazeptives implantat. |
-
1991
- 1991-12-09 IE IE427191A patent/IE71202B1/en not_active IP Right Cessation
- 1991-12-10 ZA ZA919732A patent/ZA919732B/xx unknown
- 1991-12-12 DE DE69117902T patent/DE69117902T2/de not_active Expired - Lifetime
- 1991-12-12 DE DE1999175011 patent/DE19975011I2/de active Active
- 1991-12-12 EP EP91203328A patent/EP0491443B1/en not_active Expired - Lifetime
- 1991-12-12 AT AT91203328T patent/ATE135218T1/de not_active IP Right Cessation
- 1991-12-12 ES ES91203328T patent/ES2087237T3/es not_active Expired - Lifetime
- 1991-12-12 DK DK91203328.9T patent/DK0491443T3/da active
- 1991-12-13 AU AU89678/91A patent/AU649082B2/en not_active Expired
- 1991-12-13 NZ NZ240969A patent/NZ240969A/en not_active IP Right Cessation
- 1991-12-16 PT PT99818A patent/PT99818B/pt not_active IP Right Cessation
- 1991-12-16 CA CA002057714A patent/CA2057714C/en not_active Expired - Lifetime
- 1991-12-16 KR KR1019910023066A patent/KR100221008B1/ko not_active IP Right Cessation
- 1991-12-16 NO NO914970A patent/NO178686C/no not_active IP Right Cessation
- 1991-12-16 FI FI915913A patent/FI98984C/fi active
- 1991-12-16 NO NO2002013C patent/NO2002013I2/no unknown
- 1991-12-17 CN CN91107997A patent/CN1036834C/zh not_active Expired - Lifetime
- 1991-12-17 JP JP3333717A patent/JPH04290829A/ja active Pending
-
1994
- 1994-01-19 US US08/183,644 patent/US5461041A/en not_active Expired - Lifetime
-
1996
- 1996-06-07 GR GR960401542T patent/GR3020180T3/el unknown
-
1999
- 1999-01-22 NL NL990003C patent/NL990003I2/nl unknown
- 1999-01-27 LU LU90341C patent/LU90341I2/fr unknown
Non-Patent Citations (1)
Title |
---|
Tayob et al 1985 Br. J. Obs. Gynae. 92:1003-9 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE202010010589U1 (de) | 2010-07-22 | 2010-10-14 | Bayer Schering Pharma Aktiengesellschaft | Estrogenfreie Formulierung zur oralen Kontrazeption, bevorzugt verwendbar für Frauen mit bewusster/unbewusster Laktoseintoleranz oder mit bewusster laktosefreier Kontrazeption |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0491443B1 (en) | Progestagen-only contraceptive | |
EP0491415B1 (en) | Low estrogen oral contraceptives | |
EP0912186B1 (en) | Progestogen-anti-progestogen regimens | |
EP0397823B1 (en) | Contraception system and method | |
KR100186780B1 (ko) | 피임제제 | |
US6506390B2 (en) | Progestogen-anti-progestogen regimens | |
US6642219B1 (en) | Progestogen-antiprogestogen regimens | |
WO1994004156A1 (en) | Antiprogestogen containing contraceptives | |
WO1999051214A2 (en) | Progestogen-only contraceptive kit | |
SE et al. | European Patent Specification | |
WO2000009136A1 (en) | Progestogen-only contraceptive kit providing good cycle control | |
MXPA00004610A (en) | Progestogen-antiprogestogen regimens | |
MXPA98010747A (en) | Regimes of progestogeno-anti-progestog |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19911212 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: AKZO NOBEL N.V. |
|
17Q | First examination report despatched |
Effective date: 19940617 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE |
|
REF | Corresponds to: |
Ref document number: 135218 Country of ref document: AT Date of ref document: 19960315 Kind code of ref document: T |
|
REF | Corresponds to: |
Ref document number: 69117902 Country of ref document: DE Date of ref document: 19960418 |
|
ET | Fr: translation filed | ||
ITF | It: translation for a ep patent filed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: BA2A Ref document number: 2087237 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 020872 Country of ref document: ES |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: FG4A Free format text: 3020180 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: 8364 Ref document number: 69117902 Country of ref document: DE Kind code of ref document: A |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: SPCF Free format text: 9890020, 971212 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: V448 Ref document number: 69117902 Country of ref document: DE Free format text: PRODUCT NAME: DESOGESTREL; REGISTRATION NO/DATE: 43299.00.00, 19980902 Spc suppl protection certif: 199 75 011 Filing date: 19990203 |
|
MED | It: supplementary protection certificate for pharmaceutical products: no action taken |
Free format text: CCP 650, 19990305; AKZO NOBEL N.V. |
|
REG | Reference to a national code |
Ref country code: LU Ref legal event code: CCP Free format text: LUCCP 90341, EXPIRES: 20121212 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: AC1 Free format text: NLAC1 990003, 990122 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: KC1 Free format text: NLKC1 990003, 20111212, EXPIRES: 20121211 |
|
CCPV | Be: grant of a complementary protection certificate |
Free format text: 099C0006, EXPIRES: 20121212 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: CTFF Free format text: GBCTFFSPC/GB99/019, 19990507 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: CTFG Free format text: GBCTFGSPC/GB99/019, 19991018, EXPIRES: 2012121 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: CTFG Free format text: GBCTFGSPC/GB99/019, 19991018, EXPIRES: 20121211 |
|
MEDD | It: supplementary protection certificate for pharmaceutical products: granted |
Free format text: CCP 650, 19990305; AKZO NOBEL N.V. |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CP Free format text: PRODUCT NAME: DESOGESTREL; NAT. REGISTRATION NO/DATE: NL 23 673 19991217; FIRST REGISTRATION: SE - 13 484 19971212 Spc suppl protection certif: 00C0005 Filing date: 20000131 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CR Free format text: FRCR 2000C0005, 20000131 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: SPCF Free format text: CHSPCFIKS-NR. 55155/28.03.2000, 25.07.2000 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CY Free format text: FRCY 2000C0005, 20000131, EXPIRES: 20121212 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: SPCG Free format text: PRODUCT NAME: DESOGESTRELUM; REGISTRATION NO/DATE: IKS555155 20000328 Filing date: 20000725 Extension date: 20150328 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: V457 Ref document number: 69117902 Country of ref document: DE Free format text: PRODUCT NAME: DESOGESTREL; REGISTRATION NO/DATE: 43299.00.00, 19980902 Spc suppl protection certif: 199 75 011 Filing date: 19990203 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: ISLER & PEDRAZZINI AG PATENTANWAELTE Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E |
|
NLS | Nl: assignments of ep-patents |
Owner name: N.V. ORGANON Effective date: 20061027 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: SPCM Owner name: N.V. ORGANON, NL Free format text: FORMER OWNER: AKZO NOBEL N.V., NL Spc suppl protection certif: C00491443/01 Ref country code: CH Ref legal event code: PUE Owner name: N.V. ORGANON Free format text: AKZO NOBEL N.V.#VELPERWEG 76#ARNHEM (NL) -TRANSFER TO- N.V. ORGANON#KLOOSTERSTRAAT 6#5349 AB OSS (NL) |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP |
|
NLT1 | Nl: modifications of names registered in virtue of documents presented to the patent office pursuant to art. 16 a, paragraph 1 |
Owner name: N.V. ORGANON |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: 8327 Ref document number: 69117902 Country of ref document: DE Owner name: N.V. ORGANON, OSS, NL |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: SPCN Spc suppl protection certif: C00491443/01 Representative=s name: ISLER AND PEDRAZZINI AG, CH Ref country code: CH Ref legal event code: PCAR Free format text: ISLER & PEDRAZZINI AG;POSTFACH 1772;8027 ZUERICH (CH) |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: CTFG Free format text: PRODUCT NAME: DESOGESTREL Spc suppl protection certif: CA 1999 00003 Filing date: 19990107 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20091228 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20101228 Year of fee payment: 20 Ref country code: MC Payment date: 20101124 Year of fee payment: 20 Ref country code: FR Payment date: 20110107 Year of fee payment: 20 Ref country code: AT Payment date: 20101119 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20101227 Year of fee payment: 20 Ref country code: LU Payment date: 20110103 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20110303 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20101229 Year of fee payment: 20 Ref country code: SE Payment date: 20101229 Year of fee payment: 20 Ref country code: GR Payment date: 20101228 Year of fee payment: 20 Ref country code: NL Payment date: 20101224 Year of fee payment: 20 Ref country code: IT Payment date: 20101228 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20101229 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20101224 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 69117902 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 69117902 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: V4 Effective date: 20111212 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
BE20 | Be: patent expired |
Owner name: *ORGANON N.V. Effective date: 20111212 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20111211 Ref country code: GB Ref legal event code: CTFE Free format text: PRODUCT NAME: DESOGESTREL; REGISTERED: SE 13484 19971212; UK PL00065/0159 19981109 Spc suppl protection certif: SPC/GB99/019 Filing date: 19990507 Expiry date: 20111212 Extension date: 20121211 Ref country code: NL Ref legal event code: KC1 Free format text: PRODUCT NAME: DESOGESTRELUM; NAT. REGISTRATION NO/DATE: RVG 22743 19980803; FIRST REGISTRATION: 13484 19971212 Spc suppl protection certif: C990003 Filing date: 19990122 Extension date: 20121211 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EUP |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: SPCT Owner name: MSD OSS B.V., NL Free format text: PRODUCT NAME: DESOGESTRELUM; NATIONAL REGISTRATION NO/DATE: RVG 22743 19980803; FIRST REGISTRATION: SE 13484 19971212; FORMER OWNER: N.V. ORGANON, NL Spc suppl protection certif: C990003 Filing date: 19990122 Expiry date: 20111212 Extension date: 20121211 Effective date: 20120111 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20111212 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: SPCM Owner name: MSD OSS B.V., NL Free format text: FORMER OWNER: N.V. ORGANON, NL Spc suppl protection certif: C00491443/01 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: SPCT Owner name: MSD OSS B.V., NL Free format text: PRODUCT NAME: DESOGESTREL; NAT. REGISTRATION NO/DATE: NL 23 673 19991217; FIRST REGISTRATION: 13 484 19971212 Spc suppl protection certif: 00C0005 Filing date: 20000131 Ref country code: SE Ref legal event code: EUG |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20111211 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20120305 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP Owner name: MSD OSS B.V., NL Effective date: 20120207 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: MA Ref document number: 960401542 Country of ref document: GR Effective date: 20111213 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK07 Ref document number: 135218 Country of ref document: AT Kind code of ref document: T Effective date: 20111212 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20120308 AND 20120314 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20111213 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A Owner name: MSD OSS B.V. Effective date: 20120423 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R081 Ref document number: 69117902 Country of ref document: DE Owner name: MSD OSS B.V., NL Free format text: FORMER OWNER: N.V. ORGANON, 5349 OSS, NL Spc suppl protection certif: 19975011 Filing date: 19990203 Expiry date: 20111213 Extension date: 20121212 Ref country code: DE Ref legal event code: R081 Ref document number: 69117902 Country of ref document: DE Owner name: MSD OSS B.V., KLOOSTERSTRAAT 6, NL Free format text: FORMER OWNER: N.V. ORGANON, 5349 OSS, NL Spc suppl protection certif: 19975011 Filing date: 19990203 Expiry date: 20111213 Extension date: 20121212 Ref country code: DE Ref legal event code: R082 Ref document number: 69117902 Country of ref document: DE Free format text: PRODUCT NAME: DESOGESTREL; NAT. REGISTRATION NO/DATE: 43299.00.00 19980902; FIRST REGISTRATION: SCHWEDEN 13484 19971212 Spc suppl protection certif: 19975011 Filing date: 19990203 Expiry date: 20111213 Representative=s name: WUESTHOFF & WUESTHOFF PATENT- UND RECHTSANWAEL, DE Extension date: 20121212 Ref country code: DE Ref legal event code: R082 Ref document number: 69117902 Country of ref document: DE Free format text: PRODUCT NAME: DESOGESTREL; NAT. REGISTRATION NO/DATE: 43299.00.00 19980902; FIRST REGISTRATION: SCHWEDEN 13484 19971212 Spc suppl protection certif: 19975011 Filing date: 19990203 Expiry date: 20111213 Representative=s name: WUESTHOFF & WUESTHOFF, PATENTANWAELTE PARTG MB, DE Extension date: 20121212 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R008 Ref document number: 69117902 Country of ref document: DE Free format text: PRODUCT NAME: DESOGESTREL; NAT. REGISTRATION NO/DATE: 43299.00.00 19980902; FIRST REGISTRATION: SCHWEDEN 13484 19971212 Spc suppl protection certif: 19975011 Filing date: 19990203 Expiry date: 20111213 Extension date: 20121212 Ref country code: DE Ref legal event code: R039 Ref document number: 69117902 Country of ref document: DE Free format text: PRODUCT NAME: DESOGESTREL; NAT. REGISTRATION NO/DATE: 43299.00.00 19980902; FIRST REGISTRATION: SCHWEDEN 13484 19971212 Spc suppl protection certif: 19975011 Filing date: 19990203 Expiry date: 20111213 Extension date: 20121212 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: SPCS Free format text: PRODUCT NAME: DESOGESTREL; NAT. REGISTRATION NO/DATE: NL 23 673 19991217; FIRST REGISTRATION: 13 484 19971212 Spc suppl protection certif: 00C0005 Filing date: 20000131 Name of requester: MSD FRANCE, FR |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: CCRE Owner name: *AKZO NOBEL N.V. Free format text: PRODUCT NAME: DESOGESTREL; NAT. REGISTRATION NO/DATE: 52 IS 292 F3 19980901; FIRST REGISTRATION NO/DATE: SE 13484 19971212 Spc suppl protection certif: 99C0006 Filing date: 19990601 Expiry date: 20111212 Extension date: 20121212 Effective date: 20121212 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: SPCE Free format text: PRODUCT NAME: DESOGESTREL; REGISTERED: SE 13484 19971212; UK PL00065/0159 19981109 Spc suppl protection certif: SPC/GB99/019 Filing date: 19990507 Expiry date: 20111212 Extension date: 20121211 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: SPCM Owner name: MERCK SHARP AND DOHME B.V., NL Free format text: FUSION; FORMER OWNER: ORGANON BIO SCIENCES NEDERLAND B.V., NL Spc suppl protection certif: C00491443/01 Ref country code: CH Ref legal event code: SPCM Owner name: ORGANON BIO SCIENCES NEDERLAND B.V., NL Free format text: FUSION; FORMER OWNER: MSD OSS B.V., NL Spc suppl protection certif: C00491443/01 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: SPCX Free format text: PRODUCT NAME: DESOGESTRELUM; NATL REGISTRATION NO/DATE: RVG 22743 19980803; FIRST REGISTRATION: SE 13484 19971212 Spc suppl protection certif: C990003 Filing date: 19990122 Expiry date: 20111212 Extension date: 20121211 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20111213 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R044 Ref document number: 69117902 Country of ref document: DE Free format text: PRODUCT NAME: DESOGESTREL; NAT. REGISTRATION NO/DATE: 43299.00.00 19980902; FIRST REGISTRATION: SCHWEDEN 13484 19971212 Spc suppl protection certif: 19975011 Filing date: 19990203 Expiry date: 20111213 Extension date: 20121212 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R044 Ref document number: 69117902 Country of ref document: DE Free format text: PRODUCT NAME: DESOGESTREL; NAT. REGISTRATION NO/DATE: 43299.00.00 19980902; FIRST REGISTRATION: SCHWEDEN 13484 19971212 Spc suppl protection certif: 19975011 Filing date: 19990203 Expiry date: 20111213 Extension date: 20121212 Effective date: 20140915 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: SPCL Spc suppl protection certif: C00491443/01 |